Shares of TransEnterix (NYSEMKT: TRXC), an early commercial-stage robotic surgery company, ended today’s trading session down another 16.4%. The company’s shares have now given back a healthy 22.3% of their enormous gains following the Food and Drug Administration’s (FDA) approval of its Senhance Surgical Robotic System on October 13.
Image Source: Getty Images.